ArticleOncotarget2015

Formononetin, a novel FGFR2 inhibitor, potently inhibits angiogenesis and tumor growth in preclinical models.

Xiao Yu Wu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.